Cargando…

PB2494: ADMINISTRATION OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR ENHANCED CAR T-CELL EXPANSION AND CELLULAR IMMUNITY RECOVERY WITHOUT INDUCING CYTOKINE RELEASE SYNDROME

Detalles Bibliográficos
Autores principales:	Jiang, Ying, Feng, Dan, Wang, Chun, Zhang, Yanlei, Zhao, Chuxian, LI, Su, Qin, Youwen, H. Chang, Alex, Zhu, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428896/ http://dx.doi.org/10.1097/01.HS9.0000976680.76055.be

Ejemplares similares

Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion and cellular immunity recovery without inducing cytokine release syndrome
por: Jiang, Ying, et al.
Publicado: (2022)

PB2195: MOBILIZATION WITH CYTARABINE AND GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) GIVES BETTER YIELD THAN MOBILIZATION WITH G-CSF ALONE OR COMBINED WITH CYCLOPHOSPHAMIDE
por: Simeonov, S., et al.
Publicado: (2022)

PB2446: ALLOGENEIC STEM CELL TRANSPLANTATION WITH GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) PRIMED BONE MARROW: PROSPECTIVE STUDY OF THE NATIONAL BONE MARROW TRANSPLANT CENTER IN TUNISIA
por: Yosra Kanoun, Rimmel, et al.
Publicado: (2023)

PB2314: CYTOPENIAS AND BLOOD TRANSFUSION SUPPORT AFTER CAR-T THERAPY
por: Rivada, Marcos, et al.
Publicado: (2023)

PB2202: FEATURES OF COLONY FORMING ABILITY OF BONE MARROW IN PATIENTS WITH NEUTROPENIA
por: Butolina, M., et al.
Publicado: (2022)

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
por: wang, D., et al.
Publicado: (2022)

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
por: Rui, Liu, et al.
Publicado: (2023)

PB2496: CAR-T CELLS THERAPY COMBINED WITH POMALIDOMIDE AGAINST RELAPSE AND REFRACTORY MM OR ALL WITH EXTRAMEDULLARY INVOLVEMENT
por: Zhao, Jie, et al.
Publicado: (2023)

The Effects of Ex Vivo Administration of Granulocyte-Macrophage Colony-Stimulating Factor and Endotoxin on Cytokine Release of Whole Blood Are Determined by Priming Conditions
por: Nierhaus, A., et al.
Publicado: (2017)

PB2000: LESSONS LEARNED FROM CERBA RESEARCH CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR T) MULTIPLE MYELOMA RUNNING TRIALS
por: Gaspo, R., et al.
Publicado: (2022)

PB2211: PLASMA REG3Α MAY PREDICT PROGNOSIS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH CAR-T BRIDGING TRANSPLANTATION
por: chen, M., et al.
Publicado: (2022)

PB2495: QUANTIFICATION AND IMMUNOPHENOTYPIC CHARACTERISATION OF CAR T-CELLS BY FLOW CYTOMETRY AND CORRELATION WITH CLINICAL OUTCOMES FOR PATIENTS WITH LARGE B CELL LYMPHOMA
por: Wayte, Rebecca, et al.
Publicado: (2023)

PB1790: LOOKING ‘BENEATH’ THE SURFACE: PROTEOMICS AND GLYCIPROTEOMICS REVEAL NOVEL TARGETS FOR CAR-T CELL THERAPIES IN ACUTE MYELOID LEUKEMIA (AML)
por: Brysting, Josephine, et al.
Publicado: (2023)

PB1818: PROGNOSTIC VALUE OF NEOPLASTIC INFLAMMATION AND CYTOKINES IN THE COURSE OF ACUTE MYELOID LEUKEMIA WITH MATURATION
por: Barilka, Vira, et al.
Publicado: (2023)

PB1967: ROLE OF CYTOKINES IN MULTIPLE MYELOMA: IL-1RN AND IL-4 VNTR POLYMORPHISMS
por: Serin, I., et al.
Publicado: (2022)

PB1830: THE PROGNOSTIC AND PATHOGENETIC SIGNIFICANCE OF СOMPONENTS OF NEOPLASTIC INFLAMMATION AND CYTOKINES IN THE ADULT WITH ACUTE LEUKEMIA
por: Barilka, Vira, et al.
Publicado: (2023)

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION
por: Valdes, Cesar Rodriguez, et al.
Publicado: (2023)

PB2210: FAVORABLE OUTCOME AFTER SECOND CD19 CAR T INFUSION OF AN IDENTICAL PRODUCT: HOST ENVIRONMENT AND DISEASE CHARACTERISTICS DETERMINE THE OUTCOME OF TREATMENT
por: Frölich, L., et al.
Publicado: (2022)

PB2389: DIAGNOSTIC SIGNIFICANCE OF CYTOKINE EXPRESSION LEVELS IN CEREBROSPINAL FLUID FOR CENTRAL NERVOUS SYSTEM INFILTRATION OF LYMPHOMA
por: Xin, Luo, et al.
Publicado: (2023)

PB2048: HEMATOLOGIC RECOVERY INDUCED BY AVATROMBOPAG IN SAA REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG
por: Liu, Xiaoqing, et al.
Publicado: (2023)

A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil
por: Machado, Paulo R L, et al.
Publicado: (2020)

PB2292: AMSAN VARIANT OF GUILLAIN BARRE SYNDROME COMPLICATING THE RECOVERY PHASE OF COVID-19 RELATED DISEASE
por: Haidary, A. M., et al.
Publicado: (2022)

PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA
por: Accorsi Buttini, E., et al.
Publicado: (2022)

PB2324: SAFE ADMINISTRATION OF SECOND DOSE OF MRNA COVID-19 VACCINE FOLLOWING DEVELOPMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA
por: Hajizadeh Barfejani, A., et al.
Publicado: (2022)

PB1999: ATG-010 PLUS LOW-DOSE DEXAMETHASONE (SD) IN CHINESE RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS PREVIOUSLY RECEIVED CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T)
por: Fu, W., et al.
Publicado: (2022)

PB2499: BLINATUMOMAB SEQUENTIAL ANTI-CD22 CAR-T CELLS AND HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SUCCESSFUL TREATMENT OF B LYMPHOBLASTIC LEUKEMIA EXTRAMEDULLARY RECURRENCE: A CASE REPORT
por: Yao, Hao, et al.
Publicado: (2023)

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma
por: Miller, Kevin Charles, et al.
Publicado: (2022)

Effect of Co‐administration of Granulocyte Colony‐stimulating Factor on Interferon Therapy
por: Segawa, Kotaro, et al.
Publicado: (1991)

2494. Real-World Use of Ibalizumab in Physician Office Infusion Centers (POICs)
por: Prokesch, Richard C, et al.
Publicado: (2019)

PB2341: MIDAZOLAM AND LOCAL ANAESTHESIA CO-ADMINISTRATION GIVES BETTER PAIN CONTROL DURING THE BONE MARROW ASPIRATION AND BIOPSY PROCEDURE
por: Chapanduka, Z. C.
Publicado: (2022)

PB2199: A REAL WORLD STUDY OF PEG-RHG-CSF ON HEMATOPOIETIC RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Xu, J., et al.
Publicado: (2022)

PB2451: EVALUATION OF PLATELET PARAMETERS IN PATIENTS WITH SECONDARY FAILURE OF PLATELET RECOVERY AND CYTOMEGALOVIRUS INFECTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Cao, Yigeng, et al.
Publicado: (2023)

PB2543: CIRCULATING MICROVESICLES AS POTENTIAL CELLULAR BIOMARKERS FOR THROMBOTIC RISKS IN BETA THALASSEMIA
por: Chebbi, Mariem, et al.
Publicado: (2023)

PB1702: ACTIVINA MODULATES THE MICRORNA CARGO OF EXTRACELLULAR VESICLES RELEASED BY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL) CELLS
por: Licari, Eugenia, et al.
Publicado: (2023)

The hematopoietic cytokine granulocyte-macrophage colony stimulating factor is important for cognitive functions
por: Krieger, Markus, et al.
Publicado: (2012)

PB2476: TARGETING OF BRD4 TO COUNTERACT CYTOKINE-INDUCED EXPRESSION OF PD-L1 AND PD-L2 ON VASCULAR, OSTEOBLASTIC AND STROMAL NICHE CELLS
por: Filik, Yüksel, et al.
Publicado: (2023)

PB1826: CELLULAR AND MOLECULAR CHARACTERIZATION OF THE ANTINEOPLASTIC EFFECTS OF CEPHALOCHROMIN IN MODELS OF ACUTE MYELOID LEUKEMIA
por: Nascimento, Mariane Cristina Do, et al.
Publicado: (2023)

PB1850: A DOSE FINDING AND EXPANSION OPEN LABEL, MULTICENTER STUDY OF IADADEMSTAT AND GILTERITINIB IN PATIENTS WITH RELAPSE/REFRACTORY ACUTE MYELOID LEUKEMIA WITH MUTATED FLT3: THE FRIDA STUDY
por: Fathi, A., et al.
Publicado: (2022)

PB2351: ANXIETY AT THE HEMATOLOGIST
por: Trojan, S., et al.
Publicado: (2022)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d3n1n0psms96nhlig1qt1p0avs